Oct 25, 2024 / 03:00AM GMT
Operator
Good morning, ladies and gentlemen. Welcome to the Q2 FY25 earnings conference call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Utkarsh Gandhi, General Manager, Investor Relations for Glenmark Pharmaceuticals. Thank you, and over to you, sir.
Utkarsh Gandhi Gandhi - Glenmark Pharmaceuticals Ltd - General Manager - IR
Thank you, Lisanne. Good morning, everyone. Welcome to the Q2 FY25 results conference call of Glenmark Pharmaceuticals Limited. Before we start the Q&A, we'll review the overall performance of the company for the second quarter of FY25. In Q2 FY25, Glenmark's consolidated revenue from operations was at INR34,338 million as against INR32,074 million in the corresponding quarter last year, recording an overall year-on-year growth of 7.1%.
For the six months ended September 30, 2024, Glenmark's consolidated revenue was at INR66,780 million, which is recording a Y-o-Y growth of 7%. Let's review our overall regional
Q2 2025 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Oct 25, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers